Trial Profile

RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Zotarolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms ZES-EES-OCT

Most Recent Events

07 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
07 May 2012 Planned end date changed from 1 Feb 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
10 Nov 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com